



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 29, 2023

Daniel J. O'Connor  
President and Chief Executive Officer  
New Ambrx Biopharma Inc.  
10975 North Torrey Pines Road  
La Jolla, California 92037

**Re: New Ambrx Biopharma Inc.**  
**Registration Statement on Form S-4**  
**Filed August 25, 2023**  
**File No. 333-274230**

Dear Daniel J. O'Connor:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Raymond Bogenrief, Esq.